Jeffrey J. Raizer

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Egfrviii-expressing Glioblastoma, Neuro-oncology, Act Iv +10

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Junfei Zhao, Andrew Chen, Robyn D. Gartrell et al. · Nature Medicine · 2019 · 918 citations

Neuro-oncology, Tumor Immunology, Anti-pd-1 Immunotherapy +13

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

Roger Stupp, Eric T. Wong, Andrew A. Kanner et al. · European Journal of Cancer · 2012 · 828 citations

Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome

Patrick G. Morris, Denise D. Correa, Joachim Yahalom et al. · Journal of Clinical Oncology · 2013 · 476 citations · Full text

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

David A. Reardon, Karen Fink, Tom Mikkelsen et al. · Journal of Clinical Oncology · 2008 · 470 citations · Full text